Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/16827
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Mouchemore, Kellie A | - |
dc.contributor.author | Anderson, Robin L | - |
dc.contributor.author | Hamilton, John A | - |
dc.date | 2017-08-21 | - |
dc.date.accessioned | 2017-08-31T05:39:04Z | - |
dc.date.available | 2017-08-31T05:39:04Z | - |
dc.date.issued | 2017-08-21 | - |
dc.identifier.citation | The FEBS Journal 2017; 285(4): 665-679 | en_US |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/16827 | - |
dc.description.abstract | Evidence is mounting for a role for neutrophils in breast cancer progression to metastasis. However, the role of G-CSF in neutrophil biology in a cancer setting remains to be defined. Herein we discuss the most recent clinical and experimental evidence for neutrophils and G-CSF in the promotion of metastasis, demonstrating a potential mechanistic link between them. Understanding this link is imperative both for the development of diagnostic tests and for therapies targeting neutrophils to improve the treatment of breast cancer patients with, or at risk of developing metastatic disease. Since a high neutrophil to lymphocyte ratio in patients predicts poor outcome, while mild neutropenia predicts an improved outcome, we urge caution in the use of G-CSF in neutrophil recovery following chemotherapy as there is increasing evidence in preclinical models that G-CSF can promote metastasis. | en_US |
dc.subject | Breast cancer | en_US |
dc.subject | G-CSF | en_US |
dc.subject | Metastasis | en_US |
dc.subject | Neutrophil extracellular traps | en_US |
dc.subject | Neutrophils | en_US |
dc.subject | Therapy | en_US |
dc.title | Neutrophils, G-CSF and their contribution to breast cancer metastasis | en_US |
dc.type | Journal Article | en_US |
dc.identifier.journaltitle | The FEBS Journal | en_US |
dc.identifier.affiliation | Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia | en_US |
dc.identifier.affiliation | Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia | en_US |
dc.identifier.affiliation | Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia | en_US |
dc.identifier.affiliation | La Trobe University School of Cancer Medicine, Bundoora, Victoria, Australia | en_US |
dc.identifier.affiliation | Arthritis and Inflammation Research Centre, Department of Medicine, The University of Melbourne, Royal Melbourne Hospital, Parkville, Victoria, Australia | en_US |
dc.identifier.pubmeduri | https://pubmed.ncbi.nlm.nih.gov/28834401 | en_US |
dc.identifier.doi | 10.1111/febs.14206 | en_US |
dc.type.content | Text | en_US |
dc.type.austin | Journal Article | en_US |
local.name.researcher | Anderson, Robin L | |
item.cerifentitytype | Publications | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.fulltext | No Fulltext | - |
item.openairetype | Journal Article | - |
item.grantfulltext | none | - |
crisitem.author.dept | Olivia Newton-John Cancer Research Institute | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.